Opto Circuits India's European subsidiary, EuroCor GmbH, recently had the distinction of its marquee CE-marked product - DIOR - the Paclitaxel coated Coronary Balloon Dilatation Catheter, being the first drug eluting balloon to be used in Canada. The angioplasty procedure was successfully performed by Dr Olivier Bertrand using the special access programme from Sante Canada. The data from these procedures will be included in the Valentines Trial that started on February 14, 2010.

DIOR is a drug eluting ballon which can be used safely in patients with in-stent restenosis, bifurcation lesions and lesions in small vessels.

Eurocor GmbH is providing DIOR for use in Valentine's Trial and will manage both the trial and its investigators via its own organization and the international distributor network. All data for analysis will be collected via an electronic data capture system and analyzed within the Cardiovascular Research Institute Data Coordinating Centre at Washington Hospital Centre. The study will investigate the use of drug-eluting balloons for in-stent restenosis with a follow-up in nine months and the outcomes will be announced at CRT 2011.

Dr Olivier Bertrand and Dr Rembert Pogge von Strandamann (Clinical Director, Eurocor) are invited to deliver lectures on DIOR on the second day of the Congress. The Valentines Trial which started on February 14, 2010 is a unique, first of its kind multi-centre, open-label registry of patients suffering from in-stent restenosis wherein the public will be allowed to view the procedure.

CRT 2010 is a venue for increasing clinical skills and gaining cutting edge information related to the field of interventional cardiology. Over 150 abstracts have been chosen to be presented on new data related to topics at the meeting.